Arvinas initiates patient dosing in Phase 1 ARV-110 trial
Arvinas announced the initiation of patient dosing in its Phase 1 clinical trial of ARV-110, the company's oral androgen receptor, or AR-targeted Protac protein degrader. The study will evaluate the safety, tolerability and pharmacokinetics of ARV-110 in patients with metastatic castration-resistant prostate cancer, or mCRPC, who have progressed on standard of care therapies. Arvinas believes ARV-110 is the first in a new class of targeted protein degraders to enter human clinical trials and anticipates preliminary data from the study in the second half of the year. The Phase 1 open-label, dose-escalation clinical trial will assess the safety, tolerability and pharmacokinetics of ARV-110 and is expected to enroll approximately 28-36 patients with progressive mCRPC. In addition, the study will evaluate the biochemical and clinical activity of ARV-110, by assessing prostate specific antigen levels, AR degradation, radiographic measurements of evaluable lesions and other exploratory markers of disease burden.